Evidence map›Paper›PMID 26373430›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2016

Inhibition of AMPK through Lyn-Syk-Akt enhances FcεRI signal pathways for allergic response.

Kai-Chun Lin, Duen-Yi Huang, De-Wei Huang, Shiang-Jong Tzeng, Wan-Wan Lin

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kai-Chun LinDepartment of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Duen-Yi HuangDepartment of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
De-Wei HuangDepartment of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Shiang-Jong TzengDepartment of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Wan-Wan LinDepartment of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan. wwllaura1119@ntu.edu.tw.
National Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledAMPK was shown to negatively regulate FcεRI activation, and FcεR-mediated Fyn activation can counteract the LKB1/AMPK axis in mast cells. However, the relationship between the major Src family kinase Lyn and AMPK remains poorly defined. Here, we investigate the molecular mechanism for AMPK inhibition by FcεRI-Lyn signaling in rat RBL-2H3 cells. We found that FcεRI activation could rapidly inhibit AMPK activation through increased AMPK phosphorylation at the inhibitory Ser485/491 residues without a change at the activating Th172 residue, and this was accompanied by a reduction of ACC phosphorylation. Using specific inhibitors and gene silencing, we found that such AMPK inhibition involved a signaling cascade through Lyn-Syk-Akt. When AMPK was activated by AICAR, A769662 and metformin, FcεRI-mediated Syk, ERK, JNK and p38 activation, and TNFα release were all inhibited. Consistently, AMPK inhibition by compound C increased FcεRI-mediated Lyn activation. Moreover, AMPK activation dominantly impaired IgE-induced recruitment of signal proteins to the FcεRI by blocking the formation of FcεRIβ-Lyn-Syk, FcεRIγ-Lyn-Syk, and AMPK-FcεRIβ complexes. In vitro kinase assay further revealed the ability of AMPKα2 to phosphorylate FcεRIβ in the complex. In vivo, AMPK activation by metformin could readily reduce vascular permeability and ear swelling in a mouse model of passive cutaneous anaphylaxis mediated by IgE. In summary, our findings demonstrate that IgE-mediated FcεRI activation results in AMPK inhibition through activation of Lyn-Syk-Akt pathway, and as such FcεRI receptor can efficiently propagate Lyn-mediated allergic signaling and response. These results provide important insights into the use of AMPK activators for the treatment of allergic diseases. KEY MESSAGES: AMPK is inhibited by FcεRI via Lyn-Syk-Akt signaling in RBL-2H3 cells. AMPK inhibition supports FcεRI-mediated Lyn signaling and allergic response. Metformin has inhibitory effect on passive cutaneous anaphylaxis.

Indexed as

Signal TransductionAmino Acid SequenceAMP-Activated Protein KinasesAnimalsDisease Models, AnimalHumansHypersensitivityImmunoglobulin EIntracellular Signaling Peptides and ProteinsMaleMetforminMiceMolecular Sequence DataPhosphorylationProtein BindingProtein Interaction Domains and MotifsAMP-Activated Protein KinasesImmunoglobulin EIntracellular Signaling Peptides and Proteinslyn protein-tyrosine kinaseMetforminProtein SubunitsProto-Oncogene Proteins c-aktReceptors, IgEsrc-Family KinasesSyk KinaseAktAMPKAnaphylaxisBasophilsFcεRISyk

Identifiers

PMID26373430
OpenAlexW2259765476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.